Latest News
Rani Therapeutics Holdings, Inc.
- Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances
- RANI: RT-114's Phase I PK supports a planned 2027 obesity data milestone
- Rani Therapeutics at Chardan healthcare conference: platform gains traction By Investing.com
- RANI Q2 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift Shares - Return On Capital
- Rani Therapeutics to Participate in the Chardan Healthcare Conference
- H.C. Wainwright reiterates Rani Therapeutics stock rating on FDA program acceptance
- Rani Therapeutics Holdings, Inc. Announces Acceptance Of RaniPill Capsule Platform Technology Into U.S. Food And Drug Administration Emerging Technology Program
- Rani Therapeutics’ pill platform accepted into FDA program
- Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
- Tax withholding left Rani Therapeutics (RANI) CEO Imran Talat holding 461,808 shares.
Headlines from the last 30 days, linking to the original publishers. See all market news →